65,437 trials
Postoperative Pain
Primary: Length of Hospitalization — 4.54; 4.25 days
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL
Glabellar Lines
Primary: Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial…
HIV Infections · Sexually Transmitted Diseases
Primary: Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) — 7.3; 6.7 percent of participants — p=1.00
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14 — 25.98; 26.58; 26.45; 25.93 Millimeters of mercury (mm Hg)
Rheumatoid Arthritis · Psoriatic Arthritis · Psoriasis
Primary: Baseline (Wk 0) Disease Activity Score (DAS28) — 4.54; 6.03 Score
Epilepsies · Partial
Primary: Occurrence of Treatment-emergent Adverse Events During the Study Period (Until the Time of Approval Granted) — 381 participants
Type 2 Diabetes
Primary: Serum 25-hydroxyvitamin D — 45.6; 76.2; 78.4 nmol/L
Esophageal Diseases · Gastrointestinal Diseases · Disorder of the Genitourinary System
Primary: Length of Hospital Stay (LOS) by Participant
Influenza
Primary: Number of Participants Reporting Adverse Events by System Organ Class After Vaccination With ACAM FLU A, or ACAM FLU A With Adjuvant, or a Placebo Vaccine. — 2; 2; 1; 0…
Hypertension
Primary: Watch BP Office Minus Doppler Ankle-Brachial Index Difference — 0.03 ratio
Major Depressive Disorder
Primary: Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-week Treatment Period — -1.93; -1.31 units on a scale — p=<0.001
Graft vs Host Disease · Myelodysplastic Syndromes · Leukemia
Primary: Treatment-related Mortality — 4.5 percentage of participants
Diabetic Foot Ulcer
Primary: Number of All Hemorrhages — 3 Hemorrhages
Epilepsy
Primary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event — 22; 112 participants